Small Activating RNA Molecules for Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA interference technologies primarily focus on gene silencing and have not been effectively applied to gene activation, limiting their therapeutic potential for genetic disorders.
Innovation Solution
The development of small activating RNA (saRNA) molecules that are complementary to non-coding nucleic acid sequences of target genes, which, when introduced into cells, induce specific transcriptional activation, increasing gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If short dsRNA (siRNA) is introduced into mammalian cells to achieve gene silencing, then sequence-specific inhibition of target mRNA is accomplished, but the technology cannot be applied to gene activation
Solution Approach 1:
The patent inverts the conventional siRNA approach by designing saRNA molecules with a different structural configuration and mechanism of action. Instead of using standard siRNA that recruits RNA-induced silencing complex (RISC) for degradation, the invention uses saRNA that recruits transcriptional activation complexes to achieve gene activation, effectively applying the opposite functional outcome while maintaining the small RNA format.
Solution Approach 2:
The patent changes key parameters of the RNA molecule including its length (21-23 nucleotides), structure (single-stranded with specific secondary structure), and sequence composition to enable transcriptional activation rather than silencing. These parameter changes transform the molecule's function from gene suppression to gene activation while maintaining cellular compatibility.
2Adaptability or versatility
If RNA interference technology is used for gene silencing, then therapeutic approach for genetic control is achieved, but application to gene activation for treating genetic disorders is limited
Solution Approach 1:
The patent creates a universal small RNA platform that can be adapted for both gene silencing and gene activation applications. The saRNA technology provides multi-functionality by enabling therapeutic intervention for genetic disorders that require gene activation, complementing the existing siRNA silencing approach and expanding the overall therapeutic utility of small RNA molecules.
3Reliability
If conventional siRNA approaches are applied, then mRNA degradation is achieved, but transcriptional activation capability is not obtained
Solution Approach 1:
The patent segments the RNA interference pathway into distinct functional components and creates a specialized saRNA molecule that interacts with different cellular machinery than conventional siRNA. The saRNA is designed to recruit transcriptional activation complexes rather than the RNA-induced silencing complex, effectively segmenting the application into separate silencing and activation pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SaRNAs effectively increase the expression of target genes, demonstrated by significant increases in mRNA and protein levels, and show potential in therapeutic applications such as cancer treatment by activating tumor suppressor genes.
Implementation Method 1
a small activating RNA (saRNA) molecule comprising a ribonucleic acid strand that is complementary to a non-coding nucleic acid sequence of the gene
Data Source
AI summary
The present invention provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a gene product in a cell by contacting the cell with a small activating RNA (saRNA) molecule comprising a ribonucleic strand that is complementary to a non-coding nucleic acid sequence of the gene.